1. A compound represented by the following formula (1) or pharmaceutically acceptable salt thereof:
wherein R1 and R2 are the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, or a group represented by the following formula (2);
R3 represents a hydroxy group, a lower alkoxy group which may have a substituent, a lower cycloalkyloxy group which may have a substituent, an aryloxy group which may have a substituent, \u2014NRaRb, or a group represented by the following formula (3);
R4 and R5 are the same or different and represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, or a lower alkoxy group which may have a substituent;
R6 represents a halogen atom, a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, a lower cycloalkyloxy group which may have a substituent, an aryloxy group which may have a substituent, a formyl group, a lower alkylcarbonyl group which may have a substituent, a carboxy group, a lower alkoxycarbonyl group which may have a substituent, a nitro group, a cyano group, \u2014NRcRd, or \u2014NRe(CORf);
R7 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, an aryl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, a lower cycloalkyloxy group which may have a substituent, or an aryloxy group which may have a substituent;
Ra, Rb, Rc, Rd, Re, and Rf are the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or an aryl group which may have a substituent;
the ring A represents a hydrocarbon ring or a heterocyclic ring;
the ring B represents a heterocyclic ring having one or plural heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom in the ring;
X represents a lower alkylene group which may have a substituent;
Y and Z are the same or different and represent a single bond or a lower alkylene group which may have a substituent; and
l, m, n, and o are the same or different and represent 0, 1, 2, or 3, in the case where l, m, n, and o represent 2 or 3, the respective groups represented by R4, R5, R6, or R7 may be the same or different.
2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (1),
R1 and R2 are the same or different and represent a hydrogen atom, a lower alkyl group, a lower alkyl group having a carboxy group as a substituent, a lower alkyl group having a lower alkoxycarbonyl group as a substituent, or a group represented by the following formula (2);
R3 represents a hydroxy group, a lower alkoxy group, a lower alkoxy group having a hydroxy group as a substituent, a lower alkoxy group having a lower alkoxy group as a substituent, a lower cycloalkyloxy group, an aryloxy group, \u2014NRaRb, or a group represented by the following formula (3)
R4 and R5 are the same or different and represent a halogen atom, a lower alkyl group, a hydroxy group or a lower alkoxy group;
R6 represents a halogen atom, a lower alkyl group, a lower alkyl group having a halogen atom as a substituent, a lower alkyl group having a cyano group as a substituent, a lower cycloalkyl group, an aryl group, a heterocyclic group, a heterocyclic group having a lower alkyl group as a substituent, a hydroxy group, a lower alkoxy group, a lower alkoxy group having a halogen atom as a substituent, a lower alkoxy group having a lower cycloalkyl group as a substituent, a lower alkoxy group having an aryl group as a substituent, a lower cycloalkyloxy group, an aryloxy group, a formyl group, a lower alkylcarbonyl group, a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group, \u2014NRcRd, or \u2014NRe(CORf);
R7 represents a lower alkyl group, a lower cycloalkyl group, an aryl group, a hydroxy group, a lower alkoxy group, a lower cycloalkyloxy group, or an aryloxy group;
Ra, Rb, Rc, Rd, Re, and Rf are the same or different and represent a hydrogen atom, a lower alkyl group, a lower alkyl group having \u2014NRgRh as a substituent, a lower cycloalkyl group, or an aryl group;
Rg and Rh are the same or different and represent a hydrogen atom or a lower alkyl group;
the ring A represents a hydrocarbon ring or a heterocyclic ring;
the ring B represents a heterocyclic ring having one or plural heteroatoms selected from the group consisting of a nitrogen atom and an oxygen atom in the ring;
X represents a lower alkylene group, a lower alkylene group having a hydroxy group as a substituent, or a lower alkylene group having a lower alkoxy group as a substituent;
Y and Z are the same or different and represent a single bond or a lower alkylene group; and
l, m, n, and o are the same or different and represent 0, 1, 2, or 3, in the case where l, m, n, and o represent 2 or 3, the respective groups represented by R4, R5, R6, or R7 may be the same or different.
3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (1),
R1 represents a lower alkyl group, a lower alkyl group having a carboxy group as a substituent, a lower alkyl group having a lower alkoxycarbonyl group as a substituent, or a group represented by the following formula (2);
R2 represents a hydrogen atom;
R3 represents a hydroxy group, a lower alkoxy group, a lower alkoxy group having a hydroxy group as a substituent, \u2014NRaRb, or a group represented by the following formula (3);
R5 represents a halogen atom or a lower alkoxy group;
R6 represents a halogen atom, a lower alkyl group, a lower alkyl group having a halogen atom as a substituent, a lower alkyl group having a cyano group as a substituent, a heterocyclic group, a heterocyclic group having a lower alkyl group as a substituent, a hydroxy group, a lower alkoxy group, a lower alkoxy group having a halogen atom as a substituent, a lower alkoxy group having an aryl group as a substituent, a lower alkylcarbonyl group, a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group, or \u2014NRcRd;
R7 represents a lower alkyl group or a hydroxy group;
Ra, Rb, Rc, and Rd are the same or different and represent a hydrogen atom or a lower alkyl group;
the ring A represents a hydrocarbon ring or a heterocyclic ring;
the ring B represents a heterocyclic ring having one or plural heteroatoms selected from the group consisting of a nitrogen atom and an oxygen atom in the ring;
X represents a lower alkylene group or a lower alkylene group having a hydroxy group as a substituent;
Y represents a lower alkylene group;
Z represents a single bond or a lower alkylene group;
l represents 0;
m represents 0 or 1;
n represents 0, 1, or 2, in the case where n represents 2, the two groups represented by R6 may be the same or different; and
o represents 0 or 1.
4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (1), the ring A represents a ring selected from the group consisting of cyclopentane, benzene, indan, 1,2,3,4-tetrahydronaphthalene, furan, thiophene, isoxazole, thiazole, benzo1,3dioxole, 2,3-dihydrobenzo1,4dioxin, pyridine, dihydrobenzofuran, benzimidazole, 4,5,6,7-tetrahydrobenzothiazole, and quinoline.
5. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (1), the ring B represents a ring selected from the group consisting of pyrrolidine, morpholine, piperazine piperidine, 2-pyrrolidone, and pyridine.
6. A compound or pharmaceutically acceptable salt thereof of formula (1) according to claim 1 and selected from the group consisting of
N-(2-Aminophenyl)-4-1-(2-dimethylaminoethyl)-3-phenylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(2,3-dihydroxypropyl)-3-(indan-5-yl)ureidomethylbenzamide;
N-(2-Amino-5-methoxyphenyl)-4-1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-cyclopentyl-1-(2-methylaminoethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-t-butyl-1-(3-dimethylaminopropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-dimethylaminophenyl)-1-3-(morpholin-4-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-cyanomethylphenyl)-1-(3-dimethylamino-2,2-dimethylpropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-aminopropyl)–(2,3-dihydrobenzo1,4 dioxin-6-yl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3,4-difluorophenyl)-1-(3-dimethylaminopropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-(4-methoxycarbonylphenyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-dimethylaminophenyl)-1-(2-hydroxyethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(2-hydroxyethyl)-3-phenethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-(1-ethylpyrrolidin-2-ylmethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3-methoxyphenyl)-1-3-(morpholin-4-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-difluoromethoxyphenyl)-1-3-(morpholin-4-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-(3-hydroxyphenyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3,4-difluorophenyl)-1-2-(1-methylpyrrolidin-2-yl)ethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-(pyridin-3-yl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-benzyl-1-(2-dimethylaminoethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-chlorophenyl)-1-(piperidin-4-ylmethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-(2-methoxyphenyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-ethoxycarbonylmethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-dimethylaminophenyl)-1-3-(pyrrolidin-2-on-1-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(4-dimethylaminobutyl)-3-(4-dimethylaminophenyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-2-(benzo1,3dioxol-5-yl)ethyl-1-3-(morpholin-4-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-aminophenyl)-1-3-(morpholin-4-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3-benzyloxyphenyl)-1-(3-dimethylaminopropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(2-dimethylaminoethyl)-3-phenethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-(2-methylaminoethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-phenethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3,4-dimethoxyphenyl)-1-(3-dimethylamino-2,2-dimethylpropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-(2-dimethylaminoethyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-2-(4-methylpiperazin-1-yl)ethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-(3-dimethylaminopropyl)-3-(4-fluoro-3-nitrophenyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-3-(pyrrolidin-1-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(3,4-difluorophenyl)-1-2-(4-methylpiperazin-1-yl)ethylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-3-(morpholin-4-yl)propyl-3-(3-phenylpropyl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(2,3-dihydrobenzo1,4dioxin-6-yl)-1-3-(4-methylpiperidin-1-yl)propylureidomethylbenzamide;
N-(2-Aminophenyl)-4-1-3-(morpholin-4-yl)propyl-3-(thiophen-3-yl)ureidomethylbenzamide;
N-(2-Aminophenyl)-4-3-(4-fluoro-3-methylphenyl)-1-3-(morpholin-4-yl)propylureidomethylbenzamide and
N-(2-Aminophenyl)-4-1-3-(morpholin-4-yl)propyl-3-(5-nitrothiazol-2-yl)ureidomethylbenzamide.
7. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutical carrier.
8. A method for enhancing aqueous humor outflow comprising administering to a patient a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt according to claim 1.
9. A method for lowering intraocular pressure comprising administering to a patient a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1.
10. A method for treating glaucoma or ocular hypertension comprising administering to a patient a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1.
11. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (1),
R1 represents a lower alkyl group, a lower alkyl group having a carboxy group as a substituent, a lower alkyl group having a lower alkoxycarbonyl group as a substituent, or a group represented by the following formula (2);
R2 represents a hydrogen atom;
R3 represents a hydroxy group, a lower alkoxy group, a lower alkoxy group having a hydroxy group as a substituent, \u2014NRaRb, or a group represented by the following formula (3);
R5 represents a halogen atom or a lower alkoxy group;
R6 represents a halogen atom, a lower alkyl group, a lower alkyl group having a halogen atom as a substituent, a lower alkyl group having a cyano group as a substituent, a heterocyclic group, a heterocyclic group having a lower alkyl group as a substituent, a hydroxy group, a lower alkoxy group, a lower alkoxy group having a halogen atom as a substituent, a lower alkoxy group having an aryl group as a substituent, a lower alkylcarbonyl group, a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group, or \u2014NRcRd;
R7 represents a lower alkyl group or a hydroxy group;
Ra, Rb, Rc, and Rd are the same or different and represent a hydrogen atom or a lower alkyl group;
the ring A represents a hydrocarbon ring or a heterocyclic ring;
the ring B represents a heterocyclic ring having one or plural heteroatoms selected from the group consisting of a nitrogen atom and an oxygen atom in the ring;
X represents a lower alkylene group or a lower alkylene group having a hydroxy group as a substituent;
Y represents a lower alkylene group;
Z represents a single bond or a lower alkylene group;
l represents 0;
m represents 0 or 1;
n represents 0, 1, or 2, in the case where n represents 2, the two groups represented by R6 may be the same or different; and
o represents 0 or 1.
12. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (1), the ring A represents a ring selected from the group consisting of cyclopentane, benzene, indan, 1,2,3,4-tetrahydronaphthalene, furan, thiophene, isoxazole, thiazole, benzo1,3dioxole, 2,3-dihydrobenzo1,4dioxin, pyridine, dihydrobenzofuran, benzimidazole, 4,5,6,7-tetrahydrobenzothiazole and quinoline.
13. The compound or pharmaceutically acceptable salt thereof according to claim 3, wherein in the formula (1), the ring A represents a ring selected from the group consisting of cyclopentane, benzene, indan, 1,2,3,4-tetrahydronaphthalene, furan, thiophene, isoxazole, thiazole, benzo1,3dioxole, 2,3-dihydrobenzo1,4dioxin, pyridine, dihydrobenzofuran, benzimidazole, 4,5,6,7-tetrahydrobenzothiazole, and quinoline.
14. The compound or pharmaceutically acceptable salt thereof according to claim 11, wherein in the formula (1), the ring A represents a ring selected from the group consisting of cyclopentane, benzene, indan, 1,2,3,4-tetrahydronaphthalene, furan, thiophene, isoxazole, thiazole, benzo1,3dioxole, 2,3-dihydrobenzo1,4dioxin, pyridine, dihydrobenzofuran, benzimidazole, 4,5,6,7-tetrahydrobenzothiazole, and quinoline.
15. The compound or pharmaceutically acceptable salt thereof according to claim 2, wherein in the formula (1), the ring B represents a ring selected from the group consisting of pyrrolidine, morpholine, piperazine, piperidine, 2-pyrrolidone, and pyridine.
16. The compound or pharmaceutically acceptable salt thereof according to claim 3, wherein in the formula (1), the ring B represents a ring selected from the group consisting of pyrrolidine, morpholine, piperazine, piperidine, 2-pyrrolidone, and pyridine.
17. The compound or pharmaceutically acceptable salt thereof according to claim 11, wherein in the formula (1), the ring B represents a ring selected from the group consisting of pyrrolidine, morpholine, piperazine, piperidine, 2-pyrrolidone, and pyridine.
18. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 6 and a pharmaceutical carrier.
19. A method for treating glaucoma or ocular hypertension comprising administering to a patient a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 6.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A control apparatus comprising:
a plurality of process units operating in accordance with parameters;
a storing section for storing parameters relevant to processings of the process units;
a setting section for setting predetermined parameters for the process units; and
an administration section for sending one of the parameters, which is stored in the storing section and corresponds to one of the process units, to the one of the process units in reply to a request issued by the one of the process units, transferring one of the parameters set by the setting section to a corresponding one of the process units, and rewriting the parameters stored in the storing section to the parameter set by the setting section.
2. A control apparatus according to claim 1, wherein the storing section has a memory device containing at least local parameter files storing the parameters corresponding to the process units, global parameter files storing parameters common to the process units, edit parameter files storing parameters which can be edited, and parameter control files storing parameters indicating positions of the parameters stored in the other files.
3. A control apparatus according to claim 2, wherein the files each have a source parameter file and a parameter file in which the parameters are complied in a text format.
4. A control apparatus according to claim 2, wherein the local parameter file includes a row number, a minimum value of the number of the process units, a maximum value of the number of the process units, a default value of the number of the process units, and a current value of the number of the process units.
5. A control apparatus according to claim 2, wherein the process units include a plurality of process units for performing a chemical vapor deposition process or a sputtering process, an etching process, and a thermal oxidation process, and a plurality of cassette units having a plurality of cassettes capable of containing objects to be processed, and a transfer unit for transferring the objects.
6. A control apparatus according to claim 1, wherein the setting section includes a touch screen used for inputting the parameters to the process units.
7. A control apparatus according to claim 1, further comprising a man machine interface serving as an interface between the setting section and the administration section.
8. A control apparatus according to claim 7, wherein the setting section includes a touch screen, and the man machine interface has a changeable language parameter and changes a language in which items are displayed by the touch screen.
9. A control apparatus according to claim 7, wherein the man machine interface includes a parameter for changing a first language in which items are displayed by the touch screen to a second language.
10. A control apparatus comprising:
a plurality of process units operating in reply to parameters;
a first storing section for storing parameters respectively corresponding to the process units;
a second storing section for storing parameters common to the process units;
a setting section for setting the parameter for the process units; and
an administration section for sending a parameter which is stored in one of the first and second storing sections and corresponds to one of the process units, to the one of the process units in reply to a request issued thereby, transferring the one of the parameters set by the setting section to the process unit, and rewriting the parameters stored in one of the storing sections to the parameter set by the setting section.
11. A control method comprising the steps of:
operating a plurality of process units in accordance with parameters;
preparing a storing section for storing parameters relevant to processings of the process units;
setting predetermined parameters for the process units; and
sending a stored parameter corresponding to one of the process units, to the one of the process unit in reply to a request issued thereby, transferring one of the parameters set by the setting section to corresponding tone of the process units, and rewriting the parameters stored in the storing section to the parameter set by the setting section.
12. A control method according to claim 11, wherein the storing section preparing step includes a step of preparing at least local parameter files storing the parameters corresponding to the process units, global parameter files storing parameters common to the process units, edit parameter files storing parameters which can be edited, and parameter control files storing parameters indicating positions of the parameters stored in the other files.
13. A control method according to claim 11, wherein the operating step includes a step of making the process units perform a film forming process, an etching process, and a thermal oxidation process respectively, a step of containing objects to be processed in a plurality of cassette units having a plurality of cassettes capable of containing the objects, and a step of transferring the objects from the cassette units to the process units.
14. A control method according to claim 11, further comprising the steps of displaying processes to be performed and changing a display language.
15. A control method comprising the steps of:
operating a plurality of process units in reply to parameters,
storing parameters respectively corresponding to the process units in a first storing section,
storing parameters common to the process units in a second storing section,
setting the parameters for the process units, respectively; and
sending a parameter which is stored in one of the first and second storing sections and corresponds to one of the process units, in reply to a request issued by the one of the process units, transferring one of the parameters set by the setting section to the process unit, and rewriting the parameters stored in one of the first and second storing sections to the parameters set by the setting section.